A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 882



Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Circulation 2019
Times Cited: 220




List of shared articles



Times cited

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
4


Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
38

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Daniel V O'Hara, Thomas R Parkhill, Sunil V Badve, Min Jun, Meg J Jardine, Vlado Perkovic. Diabetes Obes Metab 2021
2


Use of cardiovascular imaging in risk restratification of the diabetic patient.
Jamie W Bellinge, Sing Ching Lee, Carl J Schultz. Curr Opin Endocrinol Diabetes Obes 2021
0

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang, Zhengyuan Xia. Cardiovasc Diabetol 2021
3

Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
3

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire,[...]. Diabetes Care 2021
2

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson. Cardiovasc Diabetol 2021
1